经典霍奇金淋巴瘤自体移植后复发存活趋势改善
这项多中心回顾性研究纳入215例2005至2016年接受auto-HCT后复发的cHL患者,按移植年份分为2005-2010和2011-2016两队列。结果显示后一队列5年PR-OS为50%显著优于前者的32%,多因素分析证实移植年代、移植时年龄和复发时间是独立预后因素,提示新型疗法和异基因移植的普及改善了生存。
要点
- auto-HCT后复发的cHL患者,2011-2016年移植者5年PR-OS达50%,显著优于2005-2010年的32%。
- 移植年代、auto-HCT时年龄和复发时间是PR-OS的独立预后因素。
- 新型疗法(Bv、CPI)和allo-HCT使用增加可能驱动了生存改善。
核心结论
- cHL患者auto-HCT失败后生存近年显著改善,可能归因于新型疗法和更广泛使用allo-HCT。
研究设计与样本
- 4个美国学术中心回顾性研究,纳入2005至2016年接受auto-HCT后复发的215例cHL患者。
- 按auto-HCT年份分为队列1(2005-2010,n=118)和队列2(2011-2016,n=97)比较临床结局。
主要发现
- auto-HCT后复发5年随访时,队列1和队列2分别有32%和50%患者存活(P=.01)。
- 队列1与队列2相比,Bv使用比例55% vs 69%(P=.07),CPI使用3% vs 36%(P≤.001),allo-HCT使用22% vs 35%(P=.03)。
- 多因素分析显示队列1 vs 2的PR-OS风险比HR=2.3(95%CI 1.14-4.60;P=.01)。
- auto-HCT时年龄HR=1.48(95%CI 1.18-1.87;P≤.001),auto-HCT至复发时间HR=0.59(95%CI 0.47-74;P≤.0001)为独立预后因素。
临床怎么用
- 对于auto-HCT后复发的cHL患者,可考虑使用新型疗法如Bv和CPI以改善生存。
- allo-HCT在复发后治疗中的应用增加与生存改善相关,可作为治疗选择之一。
局限性
- 回顾性研究设计,可能存在选择偏倚和混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with classic Hodgkin lymphoma (cHL) who relapse after autologous hematopoietic cell transplantation (auto-HCT) historically have had poor outcomes. We hypothesized that, post-auto-HCT relapse, overall survival (PR-OS) has improved in recent years as a result of more widespread use of novel therapies and allogeneic HCT (allo-HCT). We conducted a retrospective study in 4 US academic centers, evaluating 215 patients who underwent auto-HCT from 2005 to 2016 and relapsed thereafter. Patients were divided into 2 cohorts based on timing of auto-HCT, 2005 through 2010 (cohort 1; n = 118) and 2011 to 2016 (cohort 2; n = 97), to compare differences in clinical outcomes. The median age and disease status at auto-HCT were similar in cohorts 1 and 2. The proportions of patients who received brentuximab vedotin (Bv; 55% vs 69%; P = .07), checkpoint inhibitors (CPIs; 3% vs 36%; P ≤ .001), and allogeneic-HCT (22% vs 35%, P = .03) were significantly different between cohorts 1 and 2, respectively. At the 5-year follow-up after auto relapse, 32% and 50% of patients were alive in cohorts 1 and 2, respectively (P = .01). In multivariate analysis for PR-OS, cohort 1 vs 2 (hazard ratio [HR], 2.3; 95% confidence interval [CI], 1.14-4.60; P = .01), age at auto-HCT (HR, 1.48; 95% CI, 1.18-1.87; P ≤ .001), and time to relapse from auto-HCT (HR, 0.59; 95% CI, 0.47-74; P ≤ .0001), retained independent prognostic significance for PR-OS. Our study supports the hypothesis that survival of cHL patients after auto-HCT failure has significantly improved in recent years, most likely because of incorporation of novel therapies and more widespread use of allo-HCT.
引用
- Badar T, Epperla N, Szabo A, et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020. PMID: 31899797. doi:10.1182/bloodadvances.2019000736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。